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Background
Colorectal cancer (CRC) is the third most common
malignancy worldwide; the leading cause of death from
this disease is progression of liver metastases. Radio-
embolisation (RE) with yttrium-90 microspheres is a
local radiotherapy treatment targeting liver metastases.
The FOXFIRE trial has randomised over 200 partici-
pants in the UK and will be open to recruitment until
May 2014.
Methodology
Eligible patients have non-resectable liver metastases
from histologically confirmed CRC with no or limited
extra-hepatic disease and no prior treatment for meta-
static disease. Each patient is randomised 1:1 to standard
chemotherapy (Oxaliplatin, Folinic Acid, 5-Flurouracil)
or chemotherapy plus RE, using minimisation with strati-
fication factors: centre, liver involvement, presence of
extra-hepatic disease and intention to treat with a biolo-
gical agent.
Recruitment issues
• Slow site activation: this trial involves complex radi-
ological intervention, involving multi-disciplinary team
working. These teams had to be formed for the trial.
This caused complex negotiations facilitated by the trials
office to encourage communication between different
departments to ensure adequate quality of care.
• Change to current the treatment paradigm affecting
recruitment: a protocol amendment was necessary to
allow the use of biological agents (cetuximab or bevaci-
zumab) with intent-to-treat with a biological agent
added as a stratum to the randomisation.
Conclusion
The key to improving recruitment has been regular
communication with the site staff, newsletters, adapting
to changing treatment paradigms, opening more sites
than originally planned and providing publicity via the
local research networks.
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